Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Name: Αlpha¹ Rigor Record — Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.
Item: Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.
Rating: 88
Author: Αlpha¹

Chen Y, Xu Y, Dai J, Sun T, Li H, Hua Z, Zhou Z, Zhou H, Yan Z, Zhao X, Xue F, Liu W, Liu X, Fu R, Wang W, Chi Y, Dong H, Ju M, Dai X, Gu W, Pei X, Yang R, Zhang L

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 3 high issues for “Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability not met−0.5★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced3 types

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed, well-reported randomised placebo-controlled phase 2 trial with a strong scientific premise, clear ethics approval, sound design, and internally consistent statistics (7/7 recomputed tests consistent). The main weaknesses are an incomplete data/code availability statement and a primary-outcome p-value reported only as a threshold (P<0.001), plus minor reporting gaps (no CONSORT reference, unlabelled ethnicity, missing vendor for the autoantibody kit).

Three independent reviewer runs of the same model were synthesised; reviewers agreed on 6 of 8 statuses and diverged on statistical analysis (pass vs warn) and data code availability (warn vs fail), reconciled here per the scoring rules. The statistics verification recomputed only 7 tests/effect estimates (those with a test statistic + df or effect + CI); threshold-only and exact p-values were not machine-verified. Citation, reproducibility, and claim-audit components found no integrity flags.

12 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks.

Reporting

Eight Dimensions7 pass · 1 fail

Prior work is cited extensively, including the pathophysiology of immune thrombocytopenia, the role of CD38, and previous anti-CD38 antibodies. The rationale for CM313 is clearly linked to the need for better treatments. Limitations of prior treatments are acknowledged, and the current study's design addresses the single-arm nature of the phase 1/2 trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The rationale is well established: ITP pathophysiology, the role of CD38 on antibody-producing cells, prior efficacy of other anti-CD38 antibodies, and the authors' own prior single-arm phase 1/2 trial all motivate this randomised trial.

Evidence

direct quote[Introduction, paragraphs 1-3]

“CD38, a type II glycoprotein abundantly expressed on antibody-producing plasmablasts and plasma cells, represents a promising therapeutic target in autoimmune diseases.”